Eurofins clinical diagnostics offers genetic tests to evaluate predisposition towards heart disease for individuals with a family history of sudden cardiac death (including sudden infant death), heart failure or transplant.
Proper assessment of CVD risk requires non-standard lipid panels that take into account HDL subpopulations. Eurofins HDL Map® takes into account the impact of the different particle sizes, composition and characteristics of those subpopulations on CVD risk. We also offer assessment of cardiometabolic syndrome (CMS) risk with a particular focus on prediabetes assessment.
Both non-standard lipids panels and genetic tests are used to provide a diagnosis. Eurofins innovative tests allow for earlier diagnosis of CVD risk and therefore better care and prognosis of patients with a cardiovascular disorder.
An understanding of metabolic pathways for production and absorption of cholesterol allow us to design the best cholesterol lowering therapy based on statins, ezetimibe, PCSK9 inhibitors, probiotics, and bile acid sequestrants. Eurofins exclusive Statin Induced Myopathy (SLCO1B1) Genotype test is used to aid in the selection of the appropriate statin for treatment, to minimize side effects and increase treatment adherence.
We offer testing for several markers that are related with disease progression and patient prognosis. Inflammation markers such as High Sensitivity C-Reactive Protein (hs-CRP), provide independent prognostic information after initiating treatment. Aortic stenosis progression as well as prediction of hospital readmission and mortality can also be evaluated with Eurofins tests.